Aarti Drugs Limited announced that CRISIL Limited has reaffirmed the company's credit ratings on its bank facilities, maintaining confidence in the pharmaceutical manufacturer's financial stability. The rating agency confirmed its assessment of the company's creditworthiness across facilities totaling Rs. 1,768 crores.

Credit Rating Details

CRISIL Limited reaffirmed both long-term and short-term credit ratings for Aarti Drugs Limited's banking facilities. The comprehensive rating covers the company's diverse financing arrangements across multiple banking partners.

Banking Partner Distribution

The rated facilities are distributed across 16 different banking institutions, demonstrating the company's diversified financing approach. Major banking partners include HDFC Bank Limited with facilities worth Rs. 300 crores across cash credit and working capital arrangements, Kotak Mahindra Bank Limited providing Rs. 433.13 crores through term loans and working capital facilities, and Axis Bank Limited contributing Rs. 225 crores in working capital facilities.

Key Banking Relationships

• HDFC Bank Limited: Rs. 300 crores (Cash Credit: Rs. 64 crores, Working Capital: Rs. 236 crores)
• Kotak Mahindra Bank Limited: Rs. 433.13 crores (Term Loan: Rs. 253.13 crores, Working Capital: Rs. 180 crores)
• Axis Bank Limited: Rs. 225 crores (Working Capital Facility)
• Proposed Working Capital Facility: Rs. 124.87 crores

Other significant banking partners include Standard Chartered Bank, Emirates NBD Bank PJSC, The Hongkong and Shanghai Banking Corporation Limited, Sumitomo Mitsui Banking Corporation, State Bank of India, Union Bank of India, RBL Bank Limited, DBS Bank Limited, and IDBI Bank Limited.

Regulatory Compliance

The company communicated this development to BSE Limited and National Stock Exchange of India Limited on January 29, 2026, pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Company Secretary and Compliance Officer Rushikesh Deole signed the regulatory filing, ensuring proper disclosure to stakeholders.

The rating letter from CRISIL remains valid until March 31, 2026, with the rating agency maintaining continuous surveillance over the company's facilities. CRISIL noted that any proposed facilities not availed within 180 days from January 29, 2026, would require fresh revalidation.

Aarti Drugs Limited has announced a scheduled board meeting to review its quarterly financial performance and consider shareholder returns through potential dividend distribution.

Board Meeting Details

The pharmaceutical company has informed stock exchanges that its Board of Directors will meet on Tuesday, February 3, 2026. The meeting has been convened under Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Key Agenda Items

The board meeting will address two primary matters of significant importance to stakeholders:

• Financial Results Approval: The directors will consider, approve and take on record the audited financial results (both standalone and consolidated) for the quarter and nine months ended December 31, 2025
• Dividend Declaration: The board will deliberate on declaring an interim dividend for FY 2025-26, subject to approval

Trading Window Restrictions

In accordance with regulatory compliance requirements, Aarti Drugs Limited has implemented trading window restrictions. The company's trading window will remain closed until 48 hours after the declaration of the financial results. This closure was previously communicated to exchanges on December 29, 2025.

Regulatory Compliance

The announcement was formally communicated to both major Indian stock exchanges through official correspondence. Company Secretary and Compliance Officer Rushikesh Vivek Deole signed the notification, ensuring adherence to disclosure requirements.

The company has made this information available on its official website at www.aartidrugs.com , ensuring transparent communication with all stakeholders regarding the upcoming board meeting and its agenda items.